A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

NCT04135352 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

35

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Neoplasm Metastasis

Interventions

DRUG: 200 mg of pembrolizumab
BIOLOGICAL: V938

Sponsor

Merck Sharp & Dohme LLC